B4T2-001 CAR-T infusions for solid tumors without chemo
Part of Cancer clinical trials.
This trial tests a new kind of cell therapy called CAR-T that targets a protein called BT-001 on solid tumors. It uses repeat infusions and avoids the strong chemotherapy usually given before treatment, which may be easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a solid tumor that is locally advanced or has spread to other parts of the body and is positive for a protein called BT-001.
- Your tumor size is less than 4 cm and can be measured on scans.
- You have finished first- or second-line standard treatment, or your doctor thinks that would be appropriate.
- Your blood counts, liver and kidney function are good enough, based on blood tests.
- You are able to care for yourself and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.